Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Business & Industry
- Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19
- AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
- Pfizer and BioNTech to submit Emergency Use Authorization request today to the U.S. FDA for COVID-19 vaccine
- Pfizer and BioNTech conclude Phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints
- Moderna's COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study
Research & Development
- European Commission approves contract with Moderna to ensure access to a potential vaccine
- New therapy for flu may help in fight against COVID-19
- The drug aprotinin inhibits entry of SARS-CoV2 in host cells
- Chinese vaccine candidate based on inactivated SARS-CoV-2 virus appears safe and induces an immune response in healthy volunteers
- Phase 2 trial of Oxford COVID-19 vaccine in healthy older adults finds it is safe and provokes immune response
- Immunological memory after cured Sars-CoV-2 infection
- European Commission approves contract with CureVac to ensure access to a potential vaccine
Conferences & Events
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
- Wearable Injectors and Connected Devices Conference 2020
Regulatory Affairs
- FDA authorizes monoclonal antibodies for treatment of COVID-19
- FDA approves first treatment for COVID-19
- Investigational COVID-19 vaccine well-tolerated, generates immune response in older adults
- EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation
- FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment